Voyager Therapeutics (NASDAQ:VYGR) Lowered to Hold at StockNews.com

StockNews.com lowered shares of Voyager Therapeutics (NASDAQ:VYGR) from a buy rating to a hold rating in a report published on Friday.

A number of other analysts also recently weighed in on VYGR. Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a report on Thursday. Wedbush decreased their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Finally, Leerink Partners initiated coverage on Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price objective on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $17.43.

Voyager Therapeutics Stock Performance

Shares of VYGR stock opened at $6.75 on Friday. The firm’s 50 day moving average price is $6.55 and its two-hundred day moving average price is $7.61. The stock has a market cap of $367.16 million, a PE ratio of -135.00 and a beta of 0.91. Voyager Therapeutics has a 52-week low of $5.71 and a 52-week high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last announced its quarterly earnings data on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The business had revenue of $29.58 million during the quarter, compared to analysts’ expectations of $11.52 million. During the same period in the previous year, the firm earned ($0.51) earnings per share. As a group, sell-side analysts predict that Voyager Therapeutics will post -1.27 earnings per share for the current fiscal year.

Insider Activity at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total transaction of $34,914.18. Following the completion of the transaction, the insider now directly owns 86,001 shares of the company’s stock, valued at $500,525.82. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.53% of the stock is currently owned by insiders.

Institutional Trading of Voyager Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC grew its position in Voyager Therapeutics by 2.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock valued at $925,000 after purchasing an additional 2,030 shares in the last quarter. Commonwealth Equity Services LLC acquired a new stake in shares of Voyager Therapeutics in the first quarter valued at about $530,000. BNP Paribas Financial Markets raised its holdings in Voyager Therapeutics by 198.6% during the first quarter. BNP Paribas Financial Markets now owns 48,769 shares of the company’s stock worth $454,000 after acquiring an additional 32,437 shares in the last quarter. Empowered Funds LLC raised its holdings in Voyager Therapeutics by 8.2% during the first quarter. Empowered Funds LLC now owns 39,471 shares of the company’s stock worth $367,000 after acquiring an additional 2,975 shares in the last quarter. Finally, ClariVest Asset Management LLC grew its position in shares of Voyager Therapeutics by 59.3% in the 1st quarter. ClariVest Asset Management LLC now owns 100,123 shares of the company’s stock valued at $932,000 after acquiring an additional 37,275 shares during the period. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.